SNHG7: A novel vital oncogenic lncRNA in human cancers
Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Yong Zhou, Bo Tian, Jinming Tang, Jie Wu, Hui Wang, Zhining Wu, Xu Li, Desong Yang, Baihua Zhang, Yuhang Xiao, Ying Wang, Junliang Ma, Wenxiang Wang, Min SuAbstractLong noncoding RNAs (lncRNAs) are a group of RNAs that lack protein-coding ability, with lengths greater than 200 nucleotides. Increasing evidence has indicated that they mediate multiple physiological and pathological processes by regulating gene expression at the epigenetic, transcriptional, post-transcriptional, and translational levels. The deregulation of lncRNAs was demonstrated to have tumor suppressive or oncogenic effects, and thus, these molecules play vital regulatory roles in tumor initiation and progression. Small nucleolar RNA hostgene 7 (SNHG7) is a lncRNA located on chromosome 9q34.3. Different studies have explored the potential role of SNHG7 in the development and progression of multiple human malignancies such as bladder, breast, colorectal, esophageal, gastric, and prostate cancer, as well as osteosarcoma, among others, and high expression predicts poor prognosis and poor survival for such patients. Moreover, this molecule can promote proliferation and metastasis, while inhibiting apoptosis in cancer cells. The present review highlights the latest insights into the expression, functional roles, and molecular mechanisms of SNHG7 in different human malignancies.
Authors: DiCaprio MR, Abousayed MM, Kambam MLR Abstract Melanoma is an aggressive form of skin cancer associated with significant morbidity and mortality. Although commonly seen in dermatologist clinics, orthopaedic surgeons must be aware of these lesions in various ways. The five common musculoskeletal manifestations of melanoma will be discussed as well as the epidemiology, pathogenesis, diagnosis, staging, treatment, and prognosis of melanoma. With an index of suspicion and awareness of melanoma, a thorough history and detailed physical examination are critical in establishing a diagnosis. An adequately performe...
Publication date: Available online 25 February 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Milan Vošmik, Miroslav Hodek, David Buka, Petra Sýkorová, Jakub Grepl, Petr Paluska, Simona Paulíková, Igor Sirák
Publication date: Available online 26 February 2020Source: Practical Radiation OncologyAuthor(s): Kimberly R. Gergelis, Cole R. Kreofsky, Christopher S. Choo, Jason Viehman, W Scott Harmsen, Scott C. Lester, Thomas M. Pisansky, Brian J. Davis, Bradley J. Stish, Richard Choo
Publication date: April 2020Source: Cancer Genetics, Volume 242Author(s):
Publication date: Available online 26 February 2020Source: Cancer GeneticsAuthor(s): Stewart G. Neill, Jennifer Hauenstein, Marilyn M. Li, Yajuan J Liu, Minjie Luo, Debra F. Saxe, Azra H. Ligon
Date: Friday, 02 28, 2020; Speaker: Dr. Weiping Zou, Professor of Pathology, Immunology, Biology&Surgery, University of Michigan School of Medicine; Building: NCI at Frederick, Building 549
CONCLUSION: Ultrasound and MRI have similar diagnostic performance for detecting parametrial infiltration in women with cervical cancer. This might have relevance from the clinical point of view, since ultrasound is cheaper than MRI. PMID: 32096793 [PubMed - as supplied by publisher]
CONCLUSION: By using the combination of ultrasound modes, this approach achieves high performance compared with the single mode and other fusion strategies. Our methodology may be a beneficial tool for the early detection and diagnosis of breast cancer. PMID: 32096788 [PubMed - as supplied by publisher]
Authors: Liu H, Li H, Li Y, Yin S, Boimel P, Janopaul-Naylor J, Zhong H, Xiao Y, Ben-Josef E, Fan Y Abstract Radiomic approaches have achieved promising performance in prediction of clinical outcomes of cancer patients. Particularly, feature dimensionality reduction plays an important role in radiomic studies. However, conventional feature dimensionality reduction techniques are not equipped to suppress data noise or utilize latent supervision information of patient data under study (e.g. difference in patients) for learning discriminative low dimensional representations. To achieve feature dimensionality reduction...
This article summarizes the associations between miR-429 and malignant tumors as well as potential action mechanisms. miR-429 has a potential to be used in the future as a biomarker for the diagnosis, treatment and prognosis of certain cancers. PMID: 31884798 [PubMed - as supplied by publisher]